Rockwell Medical (RMTI) Stock Price, News & Analysis

Company Overview

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Key Stats

• Today's Range: $1.02 to $1.06
• 50-Day Range: $0.79 to $1.29
• 52-Week Range: $0.78 to $5.15
• Volume: 71,271 shs
• Average Volume: 268,850 shs
• Market Capitalization: $35.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Rockwell Medical Stock Analysis - MarketRank™

Rockwell Medical scored higher than 87% of companies evaluated by MarketBeat, and ranked 150th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Rockwell Medical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rockwell Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rockwell Medical are expected to decrease in the coming year, from $0.03 to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rockwell Medical is -17.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rockwell Medical is -17.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rockwell Medical has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently decreased by 33.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rockwell Medical does not currently pay a dividend.

Dividend Growth

Rockwell Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

0.35% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently decreased by 33.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.20

News Sentiment

Rockwell Medical has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Rockwell Medical this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for RMTI on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

3 people have added Rockwell Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rockwell Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,758.00 in company stock.

Percentage Held by Insiders

Only 1.90% of the stock of Rockwell Medical is held by insiders.

Percentage Held by Institutions

Only 23.31% of the stock of Rockwell Medical is held by institutions.

RMTI Stock Analysis - Frequently Asked Questions

How have RMTI shares performed this year?

Rockwell Medical's stock was trading at $2.04 on January 1st, 2025. Since then, RMTI shares have decreased by 48.3% and is now trading at $1.0550.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its earnings results on Thursday, August, 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The company had revenue of $16.07 million for the quarter, compared to analyst estimates of $16.33 million. Rockwell Medical had a negative trailing twelve-month return on equity of 6.79% and a negative net margin of 2.38%.
Read the conference call transcript.

When did Rockwell Medical's stock split?

Rockwell Medical's stock reverse split on Friday, May 13th 2022.The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Who are Rockwell Medical's major shareholders?

Top institutional shareholders of Rockwell Medical include Armistice Capital LLC (6.29%), Globeflex Capital L P (0.91%), Marshall Wace LLP (0.51%) and Panagora Asset Management Inc. (0.14%). Insiders that own company stock include Larson Family Inve Irrevocable, Mark Strobeck, Timothy Chole, Jesse Neri and Mark H Ravich.
View institutional ownership trends.

How do I buy shares of Rockwell Medical?

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rockwell Medical investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Axcelis Technologies (ACLS), Opera (OPRA), ADMA Biologics (ADMA), ASML (ASML) and InterDigital (IDCC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RMTI
• CIK: 1041024
• Web: www.rockwellmed.com
• Phone: (248) 432-1362
• Fax: 248-960-9119
• Employees: 300
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Rockwell Medical: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +281.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 35.00
• P/E Growth: N/A
• Net Income: -$480 thousand
• Net Margins: -2.38%
• Pretax Margin: -2.39%
• Return on Equity: -6.79%
• Return on Assets: -3.77%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.89
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $101.49 million
• Price / Sales: 0.36
• Cash Flow: $0.13 per share
• Price / Cash Flow: 8.31
• Book Value: $0.88 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 34,430,000
• Free Float: 33,776,000
• Market Cap: $36.15 million
• Optionable: Optionable
• Beta: 1.63